The effectiveness of citicoline in the treatment of cognitive disorders

Randomized controlled trials, systematic reviews, and meta-analyses have shown that citicoline is highly effective in the treatment of vascular cognitive impairments (CI) of various origins (post-stroke, chronic cerebral ischemia (CCI)), post-traumatic CI, mild CI in neurodegenerative diseases (Alzheimer's disease, Parkinson's disease), and in patients with age-related memory impairments. Citicoline administration regimens: 1) post-stroke CI at a dose of 1000 mg/day. for a course of 4-12 months; 2) mild CI of vascular origin at a dose of 500 mg/day for a course of 3-9 months; 3) CI against the background of CCI at a dose of 500-2000 mg, the duration of the course depends on the severity of the symptoms; 4) non-demented CI at a dose of 1000 mg/day course of 9 months; 5) mild CI against Parkinson's disease at a dose of 1000 mg/day 12-18 months.

Authors

Institutions

Publication Details

Journal
S S Korsakov Journal of Neurology and Psychiatry
Published
2026-04-15
DOI
https://doi.org/10.17116/jnevro2026126031136
Primary Topic
Neurological Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The effectiveness of citicoline in the treatment of cognitive disorders

O. A. Shavlovskaya
S S Korsakov Journal of Neurology and Psychiatry
Neurological Disorders and Treatments
article

The effectiveness of citicoline in the treatment of cognitive disorders

O. A. Shavlovskaya
article en

Abstract

Randomized controlled trials, systematic reviews, and meta-analyses have shown that citicoline is highly effective in the treatment of vascular cognitive impairments (CI) of various origins (post-stroke, chronic cerebral ischemia (CCI)), post-traumatic CI, mild CI in neurodegenerative diseases (Alzheimer's disease, Parkinson's disease), and in patients with age-related memory impairments. Citicoline administration regimens: 1) post-stroke CI at a dose of 1000 mg/day. for a course of 4-12 months; 2) mild CI of vascular origin at a dose of 500 mg/day for a course of 3-9 months; 3) CI against the background of CCI at a dose of 500-2000 mg, the duration of the course depends on the severity of the symptoms; 4) non-demented CI at a dose of 1000 mg/day course of 9 months; 5) mild CI against Parkinson's disease at a dose of 1000 mg/day 12-18 months.

S S Korsakov Journal of Neurology and PsychiatryVol. 126(3)
International Institute for Restorative Practices (US), International University (KH)
Good health and well-being
Openalex Percentile: Top 12%
Neurological Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The effectiveness of citicoline in the treatment of cognitive disorders — O. A. Shavlovskaya · S S Korsakov Journal of Neurology and Psychiatry (2026) | TGRS Research Map | TGRS